Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy
- 28 September 2009
- journal article
- research article
- Published by SAGE Publications in Clinical Trials
- Vol. 6 (5), 480-490
- https://doi.org/10.1177/1740774509344633
Abstract
Background Interferon-alpha therapy, which is used to treat metastatic malignant melanoma, can cause patients to develop two distinct neurobehavioral symptom complexes: a mood syndrome and a neurovegetative syndrome. Interferon-alpha effects on serotonin metabolism appear to contribute to the mood and anxiety syndrome, while the neurovegetative syndrome appears to be related to interferon-alpha effects on dopamine. Purpose Our goal is to propose a design for utilizing a sequential, multiple assignment, randomized trial design for patients with malignant melanoma to test the relative efficacy of drugs that target serotonin versus dopamine metabolism during 4 weeks of intravenous, then 8 weeks of subcutaneous, interferon-alpha therapy. Methods Patients will be offered participation in a double-blinded, randomized, controlled, 14-week trial involving two treatment phases. During the first month of intravenous interferon-alpha therapy, we will test the hypotheses that escitalopram will be more effective in reducing depressed mood, anxiety, and irritability, whereas methylphenidate will be more effective in diminishing interferon-alpha-induced neurovegetative symptoms, such as fatigue and psychomotor slowing. During the next 8 weeks of subcutaneous interferon therapy, participants whose symptoms do not improve significantly will be randomized to the alternate agent alone versus escitalopram and methylphenidate together. Results We present a prototype for a single-center, sequential, multiple assignment, randomized trial, which seeks to determine the efficacy of sequenced and targeted treatment for the two distinct symptom complexes suffered by patients treated with interferon-alpha. Limitations Because we cannot completely control for external factors, a relevant question is whether or not ‘short-term’ neuropsychiatric interventions can increase the number of interferon-alpha doses tolerated and improve long-term survival. Conclusions This sequential, multiple assignment, randomized trial proposes a framework for developing optimal treatment strategies; however, additional studies are needed to determine the best strategy for treating or preventing neurobehavioral symptoms induced by the immunotherapy interferon-alpha. Clinical Trials 2009; 6: 480—490. http://ctj.sagepub.comThis publication has 41 references indexed in Scilit:
- Estimating Optimal Dynamic Regimes: Correcting Bias under the NullScandinavian Journal of Statistics, 2010
- Inference for non-regular parameters in optimal dynamic treatment regimesStatistical Methods in Medical Research, 2009
- Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With CancerJournal of Clinical Oncology, 2008
- From inflammation to sickness and depression: when the immune system subjugates the brainNature Reviews Neuroscience, 2008
- Developing adaptive treatment strategies in substance abuse researchDrug and Alcohol Dependence, 2007
- The treatment of depression in cancer patients: a systematic reviewSupportive Care in Cancer, 2006
- Fluoxetine Versus Placebo in Advanced Cancer Outpatients: A Double-Blinded Trial of the Hoosier Oncology GroupJournal of Clinical Oncology, 2003
- Reinforcement Learning: An IntroductionIEEE Transactions on Neural Networks, 1998
- Analysis of Semiparametric Regression Models for Repeated Outcomes in the Presence of Missing DataJournal of the American Statistical Association, 1995
- Estimation of Regression Coefficients When Some Regressors are not Always ObservedJournal of the American Statistical Association, 1994